FDA approves anti-nausea patch for chemotherapy patients
BEDMINSTER, N.J. The Food and Drug Administration has approved ProStrakan’s drug Sancuso to treat nausea and vomiting in patients receiving certain types of chemotherapy, ProStrakan announced Monday.
The drug is a patch, known generically as granisetron transdermal system, designed for patients whose chemotherapy regimens are moderately or highly likely to produce chemotherapy-induced nausea and vomiting. Left untreated, CINV can lead to dehydration, malnutrition, treatment delay or discontinuation of treatment and is often considered a feared side effect.
“We’ve made significant progress in our understanding of chemotherapy and how to prevent its side effects, yet undergoing chemotherapy remains a challenging experience on many levels,” said Barbara Rogers, a nurse practitioner at Fox Chase Cancer Center. “We should have zero tolerance for CINV.”
Bayer denies takeover rumors
FRANKFURT, Germany Reports of Bayer’s imminent takeover appear greatly exaggerated.
The company’s chief executive officer told a German newspaper that it would not be taken over, amid rumors last week that Pfizer sought to acquire it. But Bayer has a number of drugs in its research pipeline, while many of Pfizer’s blockbuster drugs will soon go off patent, facing competition from generic drug makers.
MyMedSchedule now available to the public
INDIANAPOLIS A service that helps people with organ transplants manage their medication schedules has become available to the public.
MyMedSchedule used to be available only in hospitals, reminding organ transplant recipients to take their medications and helping them avoid errors. People who have received transplants often must take several drugs to avoid rejection of the new organs.
Companies such as Community Health Network and the American Society of Health-System Pharmacists offer similar services.